Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. This result, published online ...
Feb 14, 2019
0
4
Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens. These results reveal a direct pathway ...
Jan 24, 2019
1
1
The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc., announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety and tolerability of a ...
Jan 8, 2019
0
2
Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream. Results of preclinical ...
Nov 15, 2018
0
0
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...
Nov 13, 2018
0
58
According to new research from The Wistar Institute, the S100A14 protein is expressed at higher levels in people who inject drugs and remain uninfected despite many years of high-risk, needle sharing behavior in areas with ...
Nov 13, 2018
0
2
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...
Oct 15, 2018
0
77
A novel synthetic DNA vaccine developed based on technology pioneered by scientists at The Wistar Institute Vaccine & Immunotherapy Center offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical ...
Oct 10, 2018
0
12
Scientists at The Wistar Institute have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene. The study, published in Nature Communications, suggests that inhibition ...
Oct 9, 2018
0
21
Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule ...
Oct 4, 2018
0
33
